2017 News Releases
2017 News Releases
CSL and Vitaeris Announce Strategic Partnership with Option to Acquire
The two companies have entered into a strategic collaboration and purchase option agreement to expedite the development of clazakizumab (an anti-IL6 MAB, formerly ALD518) as a therapeutic option for solid organ transplant rejection.
Lancet Neurology Publishes Results from CSL Behring Phase III Study of Hizentra® (Immune Globulin Subcutaneous [Human] 20% liquid) as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Hizentra PATH study, the largest controlled clinical study in patients with CIDP, met its primary endpoint
Data on the Preventive Effects of HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) in Subjects with Very Frequent HAE Attacks Presented by CSL Behring at the 2017 ACAAI Annual Scientific Meeting
A subgroup analysis of data from the Phase III COMPACT trial showed 98 percent median reduction in hereditary angioedema (HAE) attacks per month in subjects who experienced at least one attack per week while on placebo
New Data for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) to be presented at the 2017 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
- HAEGARDA is the first and only subcutaneous preventive treatment option for HAE in the US
- Oral presentation will highlight the preventive effect of HAEGARDA in HAE patients with a high frequency of attacks
CSL Behring Trains Employees to Save Lives in Their Communities and Workplace with CPR; AHA Encourages Other Businesses to Do the Same
There are more than 350,000 cardiac arrests annually in the U.S.; nearly 90 percent are fatal but when CPR is administered immediately, chances of survival can triple.
Japan’s Ministry of Health, Labour and Welfare Approves AFSTYLA® - CSL Behring’s Novel Recombinant Haemophilia A Treatment
AFSTYLA® is the first and only single-chain recombinant factor VIII specifically designed to treat hemophilia A
Patient Groups Sharpen Their Capabilities to Protect Access to Medicines for Treating Rare Bleeding Disorders
CSL Behring’s LEAD grant is helping them advocate more effectively in a shifting health care environment.
CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State
CSL Behring commits $4.92 million to Penn State's multidisciplinary Center of Excellence in Biotechnology
CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
Privigen shown to improve functional abilities in patients with a rare neurological condition
CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI
Immunoglobulin Leader Donates €15,000 to International Patient Organisation to Support Primary Immunodeficiency Awareness Initiatives
CSL Behring Presents New Alpha 1 Antitrypsin Deficiency Treatment Data at Global ERS Congress
- Symposium “Transitioning Clinical Data into Patient Care – Recent Real-Life Experiences with Alpha 1”
- RAPID and RAPID extension trial data to be featured in poster and oral presentations
CSL Behring Joins Together With Others Around the World—Sponsoring the 2017 Meeting of the European Society for Immunodeficiencies (ESID)
Biotherapeutics leader to map attendee visits to result in a donation to International Patient Organisation for Primary Immunodeficiencies (IPOPI)
HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
- First and only subcutaneous preventive treatment option reduced HAE attacks by 95 percent (median) in treated patients
- Comprehensive support program offered to patients
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])
FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks
FDA Accepts CSL Behring’s Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
For the treatment for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.
New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Hemophilia B
Findings presented at the International Society on Thrombosis and Haemostasis Congress 2017 show product’s impact on treatment adherence, consumption and quality of life
CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders
CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards
New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A
Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017
New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017
New findings demonstrate CSL Behring’s promise to develop and deliver innovative treatments that improve patients’ lives
FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema
- HAEGARDA has been shown to reduce HAE attacks by 95 percent (median) in patients with a life-threatening, rare genetic disorder
- Use of rescue medication was reduced by greater than 99 percent (1)
- Subcutaneous administration builds and maintains steady-state C1-INH levels